Harrow, Inc. (HROW) vs Xeris Biopharma Holdings, Inc. (XERS)
- Harrow, Inc. HROW 27.28 −5.11%
- Xeris Biopharma Holdings, Inc. XERS 10.28 +2.09%
Harrow, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Xeris Biopharma Holdings, Inc. is the larger, with a market value of $1.8B against $1.1B — 1.7× the size. Xeris Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 36.3% against 21.1%. Xeris Biopharma Holdings, Inc. has the higher net margin (−5.12% vs −13.5%) and the higher return on invested capital (18.9% vs −0.77%). Across the 18 metrics below, Xeris Biopharma Holdings, Inc. leads on 15 and Harrow, Inc. on 3.
Valuation
Profitability
| Metric | HROW | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 73.28% | 86.58% | 53.94% |
| Operating margin | (1.00%) | 10.91% | 0.00% |
| Net margin | (13.51%) | (5.12%) | 0.00% |
| Free cash flow margin | (4.75%) | 16.60% | 0.00% |
| Return on equity | (116.07%) | 118.22% | (0.40%) |
| Return on assets | (9.77%) | (4.60%) | (3.32%) |
| Return on invested capital | (0.77%) | 18.88% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack